According to TipRanks, Sergott is a 3-star analyst with an average return of 1.7% and a 38.27% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Icon, Thermo Fisher, and IQVIA Holdings.
Currently, the analyst consensus on Avantor is a Moderate Buy with an average price target of $35.40.
Based on Avantor’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.91 billion and a net profit of $187.4 million. In comparison, last year the company earned a revenue of $1.86 billion and had a net profit of $157.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
Read More on AVTR:
- Barclays Sticks to Its Buy Rating for Thermo Fisher (TMO)
- PerkinElmer (PKI) Receives a Sell from Barclays
- Barclays Sticks to Their Hold Rating for Elanco Animal Health (ELAN)
- Barclays Sticks to Their Buy Rating for IQVIA Holdings (IQV)
- Rosenblatt Securities Sticks to Their Buy Rating for Arteris (AIP)